These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of hereditary tyrosinaemia (type 1) through the LSDP
- Drugs currently available for the treatment of hereditary tyrosinaemia (type 1) through the LSDP
- Choice of treatment
- Dosage
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Guidelines
About this resource
Publication date:
Publication type:
Guideline
Language:
English
Part of a collection: